stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Revenue growth
Ligand Pharmaceuticals Incorporated's revenue growth over the twelve months to 30 September 2026 was 1.03%, down 59.4 percentage points from fiscal 2025 (60.4%). Over the past ten years it has ranged from −52.2% (fiscal 2019) to 78.2% (fiscal 2018); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 60.4% | 33.12 |
| FY2024 | 27.3% | 60.37 |
| FY2023 | −33.1% | (14.34) |
| FY2022 | −18.8% | (66.43) |
| FY2021 | 47.7% | 11.70 |
| FY2020 | 36.0% | 88.15 |
| FY2019 | −52.2% | (130.38) |
| FY2018 | 78.2% | 48.73 |
| FY2017 | 29.5% | (22.05) |
| FY2016 | 51.5% | 40.10 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −31.8% | (65.53) |
| Jun 2026 | 33.7% | 19.64 |
| Mar 2026 | 14.1% | (25.28) |
| Dec 2025 | 39.4% | (83.48) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. compare | 840.8% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 42.2% |
| LGND Ligand Pharmaceuticals Incorporated | 1.03% |
| IONS Ionis Pharmaceuticals, Inc. compare | −7.41% |
| PTCT PTC Therapeutics, Inc. compare | −35.1% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement